{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-016746","form_type":"8-K","ticker":"INBS","cik":"0001725430","company_name":"INTELLIGENT BIO SOLUTIONS INC.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.254511+00:00","generated_at":"2026-06-15T02:39:10.707354+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Intelligent Bio Solutions posts Q3 net loss $6.34M on $457K rev; goodwill impairment $4.1M","bullets":["Combined revenue & govt support $574,738 (+199% YoY); product revenue $457,058 from Intelligent Fingerprinting acquisition.","Net loss $6.34M ($5.72 per share) vs $1.34M ($1.79) prior year; includes $4.1M non-cash goodwill impairment.","Filed 513(g) FDA submission for drug screening cartridge; granted UK patent for DSR-Plus Cartridge Reader (13th patent).","Completed biosensor Milestone 7: 4x improvement in time-to-result (<1 min); advancing to human saliva testing.","Cash and equivalents $2.3M as of March 31, 2023; new sales team and distribution hub established in Australia."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-016746","json":"https://secwatch.observer/filing/0001493152-23-016746.json","markdown":"https://secwatch.observer/filing/0001493152-23-016746.md","text":"https://secwatch.observer/filing/0001493152-23-016746.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725430/000149315223016746/0001493152-23-016746-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725430/000149315223016746/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:39:10.707354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"273aa1dac3898e4ab1388d180db35ebf8488157b","claim":"INTELLIGENT BIO SOLUTIONS INC. reported fiscal third quarter ended March 31, 2023 results: revenue $457,058, net income $6.34 million, EPS $5.72 per share.","evidence_excerpt":"The Company’s combined revenue and government support income increased by 199% or $382,238 to $574,738 for the three months ending March 31, 2023, including revenue of $457,058, compared to the same period in 2022. The year-over-year revenue increase reflects the acquisition of Intelligent Fingerprinting Ltd. during the fiscal 2023 second quarter and the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725430/000149315223016746/0001493152-23-016746-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal third quarter ended March 31, 2023"},{"label":"Revenue","value":"$457,058"},{"label":"Net income","value":"$6.34 million"},{"label":"EPS","value":"$5.72 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}